A Phase 1 interventional study of Romosozumab and Placebo in Osteopenia, sponsored by Amgen. Completed. Open to female participants aged 55 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-05.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing romosozumab in Bone Diseases, Metabolic — none open to participants now, 1 under way, none of them phase 3. romosozumab · Bone Diseases, Metabolic.
Among the 11 studies testing romosozumab in Bone Diseases, Metabolic, this one is the 10th largest by enrollment, is one of 2 that started in 2009, is one of 4 in phase 1, and was the 2nd registered.
662 studies on the registry are indexed under Bone Diseases, Metabolic; 94 are open to participants now.
Browse Bone Diseases, Metabolic studies →None of the 11 studies testing romosozumab in Bone Diseases, Metabolic is open now. The open studies under Bone Diseases, Metabolic, anywhere →
romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 64 Bone Diseases, Metabolic studies recruiting now, 28 (44%) set no upper age limit and 28 (44%) stop at 75 or younger; 12 take children under 18; 22 take healthy volunteers.
This study: 55 Years to 80 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2009.
This study's enrollment of 24 is below the median of 60 across 509 interventional studies indexed under Bone Diseases, Metabolic.
Median enrollment 74 across the 11 interventional studies. Of the 10 that completed or were terminated, 10 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 3 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
23 studies in Bone Diseases, Metabolic by Amgen: none open now, none under way, none of them phase 3. Of 23 finished, 21 (91%) have results posted.
Among the 23 studies in Bone Diseases, Metabolic by Amgen, this one is the 21st largest by enrollment, is one of 7 that started in 2009, is one of 7 in phase 1, and was the 13th registered.
Amgen’s Bone Diseases, Metabolic studies by the year they started, since 2002.
1 of the studies testing romosozumab in Bone Diseases, Metabolic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05058976Susan L. GreenspanRomosozumab Use to Build Skeletal Integrity | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing romosozumab in Bone Diseases, Metabolic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 23 in Bone Diseases, Metabolic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of romosozumab on parameters of bone quality of the forearm using peripheral quantitative computed tomography (pQCT) following multiple subcutaneous dose administrations of romosozumab in postmenopausal women with low bone mass.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
females (based on medical history) defined as 12 continuous months of spontaneous amenorrhea
Exclusion Criteria:
Administration of the following medications within 6 months before study drug administration. This includes all routes of administration, for example intranasal and topical skin patches, unless otherwise noted:
Administration of daily, weekly, or monthly bisphosphonates (BP) unless meeting the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were randomized to receive matching placebo administered by subcutaneous injection once every 4 weeks (Q4W) for 3 months.
Drug: Placebo
Participants were randomized to receive 3 mg/kg romosozumab administered by subcutaneous injection once every 4 weeks (Q4W) for 3 months.
Drug: Romosozumab
Administered by subcutaneous injection
Also known as: AMG 785, EVENITY™
Administered by subcutaneous injection
Percent Change From Baseline in Polar Cross-sectional Moment of Inertia at the Distal Radius
The polar moment of inertia is a geometric measurement used to predict bone quality, specifically the ability to resist torsion (twisting), and is highly correlated with fracture load at the distal radius. The polar cross-sectional moment of inertia was assessed using peripheral quantitative computed tomography (pQCT), a 3-dimensional imaging technology which can be used for volumetric analysis of appendicular skeletal sites such as the arms and the legs. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
Time frame: Baseline and days 29, 57, 85, 127, and 169
Percent Change From Baseline in Total Bone Area at the Distal Radius
Total bone area was assessed using peripheral quantitative computed tomography (pQCT), a 3-dimensional imaging technology which can be used for volumetric analysis of appendicular skeletal sites such as the arms and the legs. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
Time frame: Baseline and days 29, 57, 85, 127, and 169
Percent Change From Baseline in Total Bone Mineral Content at the Distal Radius
Total bone mineral content was assessed using peripheral quantitative computed tomography (pQCT). The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
Time frame: Baseline and days 29, 57, 85, 127, and 169
Percent Change From Baseline in Total Bone Mineral Density at the Distal Radius
Total bone mineral density was assessed using peripheral quantitative computed tomography (pQCT). The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
Time frame: Baseline and days 29, 57, 85, 127, and 169
Percent Change From Baseline in Cortical Bone Area at the Distal Radius
Cortical bone area was assessed using peripheral quantitative computed tomography (pQCT). The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
Time frame: Baseline and days 29, 57, 85, 127, and 169
Percent Change From Baseline in Cortical Bone Mineral Content at the Distal Radius
Cortical bone mineral content was assessed using peripheral quantitative computed tomography (pQCT). The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
Time frame: Baseline and days 29, 57, 85, 127, and 169
Percent Change From Baseline in Cortical Bone Mineral Density at the Distal Radius
Cortical bone mineral density was assessed using peripheral quantitative computed tomography (pQCT). The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
Time frame: Baseline and days 29, 57, 85, 127, and 169
Percent Change From Baseline in Endocortical Circumference at the Distal Radius
Endocortical circumference was derived from pQCT measurements based on applying a circular ring model to the cortical shell. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
Time frame: Baseline and days 29, 57, 85, 127, and 169
Percent Change From Baseline in Periosteal Circumference at the Distal Radius
Periosteal circumference was derived from pQCT measurements based on applying a circular ring model to the cortical shell. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
Time frame: Baseline and days 29, 57, 85, 127, and 169
Percent Change From Baseline in Cortical Thickness at the Distal Radius
Cortical thickness was derived from pQCT measurements based on applying a circular ring model to the cortical shell. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
Time frame: Baseline and days 29, 57, 85, 127, and 169
Percent Change From Baseline in Polar Section Modulus at the Distal Radius
Polar section modulus is a measurement of bone strength and was derived from pQCT measurements. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
Time frame: Baseline and days 29, 57, 85, 127, and 169
Percent Change From Baseline in Polar Strength Strain Index at the Distal Radius
The polar strength strain index is a measurement of bone strength and was derived from pQCT measurements. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
Time frame: Baseline and days 29, 57, 85, 127, and 169
Percent Change From Baseline in Axial Moment of Inertia at the Distal Radius
Axial moment of inertia is an indicator of the ability of bone to resist bending, and was derived from pQCT measurements based on a circular ring model. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
Time frame: Baseline and days 29, 57, 85, 127, and 169
Percent Change From Baseline in Total Bone Area at the Ultradistal Radius
Total bone area was assessed using peripheral quantitative computed tomography (pQCT), a 3-dimensional imaging technology which can be used for volumetric analysis of appendicular skeletal sites such as the arms and the legs. The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
Time frame: Baseline and days 29, 57, 85, 127, and 169
Percent Change From Baseline in Total Bone Mineral Content at the Ultradistal Radius
Total bone mineral content was assessed using peripheral quantitative computed tomography (pQCT). The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
Time frame: Baseline and days 29, 57, 85, 127, and 169
Percent Change From Baseline in Total Bone Mineral Density at the Ultradistal Radius
Total bone mineral density was assessed using peripheral quantitative computed tomography (pQCT). The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
Time frame: Baseline and days 29, 57, 85, 127, and 169
Percent Change From Baseline in Trabecular Bone Area at the Ultradistal Radius
Trabecular bone area was assessed using peripheral quantitative computed tomography (pQCT). The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
Time frame: Baseline and days 29, 57, 85, 127, and 169
Percent Change From Baseline in Trabecular Bone Mineral Content at the Ultradistal Radius
Trabecular bone mineral content was assessed using peripheral quantitative computed tomography (pQCT). The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
Time frame: Baseline and days 29, 57, 85, 127, and 169
Percent Change From Baseline in Trabecular Bone Mineral Density at the Ultradistal Radius
Trabecular bone mineral density was assessed using peripheral quantitative computed tomography (pQCT). The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
Time frame: Baseline and days 29, 57, 85, 127, and 169
Percent Change From Baseline in Polar Strength Strain Index at the Ultradistal Radius
The polar strength strain index is a measurement of bone strength and was derived from pQCT measurements. The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
Time frame: Baseline and days 29, 57, 85, 127, and 169
Percent Change From Baseline in Bone Mineral Density at the One-third Radius
Bone mineral density was assessed using dual energy x-ray absorptiometry (DXA). Scans were analyzed by a central reader.
Time frame: Baseline and days 29, 57, 85, 127, and 169
Percent Change From Baseline in Bone Mineral Density at the Total Wrist
Bone mineral density was assessed using dual energy x-ray absorptiometry (DXA). Scans were analyzed by a central reader.
Time frame: Baseline and days 29, 57, 85, 127, and 169
Percent Change From Baseline in Bone Mineral Density at the Total Lumbar Spine
Bone mineral density was assessed using dual energy x-ray absorptiometry (DXA). Scans were analyzed by a central reader.
Time frame: Baseline and days 85 and 169
Percent Change From Baseline in Serum Procollagen Type 1 N-terminal Propeptide (P1NP)
Time frame: Baseline and days 4, 15, 29, 57, 62, 71, 85, 99, 127, and 169
Percent Change From Baseline in Serum C-Telopeptide (sCTX)
Time frame: Baseline and days 4, 15, 29, 57, 62, 71, 85, 99, 127, and 169
Time to Maximum Serum Concentration (Tmax) of Romosozumab
Serum concentrations of romosozumab were measured by a validated enzyme-linked immunosorbent assay. The lower limit of quantification (LLOQ) was 50 ng/mL.
Time frame: First Dose: Day 1 (predose) and on days 4, 15, and 29 (predose). Last Dose: Days 57 (predose), 62, 71, 85, 99, 127, and 169
Maximum Serum Concentration (Cmax) of Romosozumab
Serum concentrations of romosozumab were measured by a validated enzyme-linked immunosorbent assay. The lower limit of quantification (LLOQ) was 50 ng/mL.
Time frame: First Dose: Day 1 (predose) and on days 4, 15, and 29 (predose). Last Dose: Days 57 (predose), 62, 71, 85, 99, 127, and 169
Area Under the Serum Concentration-time Curve From Time 0 to Tau (AUC0-28)
Serum concentrations of romosozumab were measured by a validated enzyme-linked immunosorbent assay. The lower limit of quantification (LLOQ) was 50 ng/mL. The area under the serum drug concentration-time curve from time zero to tau (tau = 28 days) (AUC0-28) was calculated by the linear trapezoidal method.
Time frame: First Dose: Day 1 (predose) and on days 4, 15, and 29 (predose). Last Dose: Days 57 (predose), 62, 71, 85, 99, 127, and 169
Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf)
Serum concentrations of romosozumab were measured by a validated enzyme-linked immunosorbent assay. The lower limit of quantification (LLOQ) was 50 ng/mL.
Time frame: Last Dose: Days 57 (predose), 62, 71, 85, 99, 127, and 169
Apparent Clearance (CL/F) of Romosozumab
Serum concentrations of romosozumab were measured by a validated enzyme-linked immunosorbent assay. The lower limit of quantification (LLOQ) was 50 ng/mL.
Time frame: Last Dose: Days 57 (predose), 62, 71, 85, 99, 127, and 169
Terminal Half-life (t1/2,z) of Romosozumab
Serum concentrations of romosozumab were measured by a validated enzyme-linked immunosorbent assay. The lower limit of quantification (LLOQ) was 50 ng/mL.
Time frame: Last Dose: Days 57 (predose), 62, 71, 85, 99, 127, and 169
Accumulation Ratio
Accumulation ratio was calculated as the ratio of AUC0-28 after the last dose to AUC0-28 after the first dose.
Time frame: First Dose: Day 1 (predose) and on days 4, 15, and 29 (predose). Last Dose: Days 57 (predose), 62, 71, 85, 99, 127, and 169
This study was conducted at a single center in the United States.
| Milestone | Placebo | Romosozumab |
|---|---|---|
| Started | 12 | 12 |
| Completed | 11 | 11 |
| Not completed | 1 | 1 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
The polar moment of inertia is a geometric measurement used to predict bone quality, specifically the ability to resist torsion (twisting), and is highly correlated with fracture load at the distal radius. The polar cross-sectional moment of inertia was assessed using peripheral quantitative computed tomography (pQCT), a 3-dimensional imaging technology which can be used for volumetric analysis of appendicular skeletal sites such as the arms and the legs. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Day 29 | -1.16 ± 1.40 | 0.16 ± 0.95 |
| Day 57 | -1.03 ± 1.00 | -1.03 ± 1.19 |
| Day 85 | -2.28 ± 1.21 | 1.45 ± 1.03 |
| Day 127 | -1.93 ± 1.22 | 0.87 ± 0.89 |
| Day 169 | -1.66 ± 1.22 | -0.08 ± 1.12 |
Total bone area was assessed using peripheral quantitative computed tomography (pQCT), a 3-dimensional imaging technology which can be used for volumetric analysis of appendicular skeletal sites such as the arms and the legs. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Day 29 | -0.07 ± 0.56 | -0.21 ± 0.40 |
| Day 57 | -0.08 ± 0.48 | -0.13 ± 0.56 |
| Day 85 | -0.79 ± 0.49 | 0.38 ± 0.61 |
| Day 127 | 0.05 ± 0.43 | 0.87 ± 0.66 |
| Day 169 | -0.23 ± 0.46 | -0.04 ± 0.70 |
Total bone mineral content was assessed using peripheral quantitative computed tomography (pQCT). The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Day 29 | -0.39 ± 0.40 | -0.27 ± 0.41 |
| Day 57 | -0.33 ± 0.37 | -0.49 ± 0.27 |
| Day 85 | -0.86 ± 0.47 | -0.51 ± 0.36 |
| Day 127 | -0.66 ± 0.36 | -0.43 ± 0.37 |
| Day 169 | -1.34 ± 0.30 | -1.09 ± 0.36 |
Total bone mineral density was assessed using peripheral quantitative computed tomography (pQCT). The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Day 29 | -0.30 ± 0.48 | -0.06 ± 0.30 |
| Day 57 | -0.24 ± 0.38 | -0.34 ± 0.44 |
| Day 85 | -0.07 ± 0.19 | -0.86 ± 0.53 |
| Day 127 | -0.69 ± 0.48 | -1.26 ± 0.53 |
| Day 169 | -0.10 ± 0.42 | -1.02 ± 0.55 |
Cortical bone area was assessed using peripheral quantitative computed tomography (pQCT). The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Day 29 | -0.27 ± 0.58 | 0.06 ± 0.63 |
| Day 57 | -0.05 ± 0.54 | -0.53 ± 0.64 |
| Day 85 | -1.39 ± 0.77 | 0.69 ± 0.67 |
| Day 127 | -1.41 ± 0.81 | 0.28 ± 0.63 |
| Day 169 | -1.59 ± 0.58 | -0.50 ± 0.74 |
Cortical bone mineral content was assessed using peripheral quantitative computed tomography (pQCT). The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Day 29 | -0.33 ± 0.57 | 0.07 ± 0.46 |
| Day 57 | -0.29 ± 0.52 | -0.86 ± 0.45 |
| Day 85 | -1.08 ± 0.66 | -0.07 ± 0.66 |
| Day 127 | -1.45 ± 0.82 | -0.66 ± 0.57 |
| Day 169 | -1.69 ± 0.55 | -1.29 ± 0.67 |
Cortical bone mineral density was assessed using peripheral quantitative computed tomography (pQCT). The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Day 29 | -0.06 ± 0.10 | 0.02 ± 0.21 |
| Day 57 | -0.24 ± 0.21 | -0.32 ± 0.28 |
| Day 85 | 0.32 ± 0.24 | -0.76 ± 0.23 |
| Day 127 | -0.04 ± 0.23 | -0.92 ± 0.40 |
| Day 169 | -0.10 ± 0.23 | -0.79 ± 0.31 |
Endocortical circumference was derived from pQCT measurements based on applying a circular ring model to the cortical shell. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Day 29 | 0.20 ± 0.74 | -0.19 ± 0.50 |
| Day 57 | -0.23 ± 0.73 | 0.26 ± 0.67 |
| Day 85 | -0.03 ± 0.39 | -0.07 ± 0.72 |
| Day 127 | 0.77 ± 0.80 | 0.89 ± 0.66 |
| Day 169 | 0.85 ± 0.66 | 0.49 ± 0.84 |
Periosteal circumference was derived from pQCT measurements based on applying a circular ring model to the cortical shell. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Day 29 | -0.04 ± 0.28 | -0.11 ± 0.20 |
| Day 57 | -0.04 ± 0.24 | -0.07 ± 0.28 |
| Day 85 | -0.40 ± 0.25 | 0.19 ± 0.31 |
| Day 127 | 0.02 ± 0.22 | 0.43 ± 0.33 |
| Day 169 | -0.12 ± 0.23 | -0.02 ± 0.35 |
Cortical thickness was derived from pQCT measurements based on applying a circular ring model to the cortical shell. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Day 29 | -0.29 ± 0.82 | 0.22 ± 0.77 |
| Day 57 | 0.09 ± 0.79 | -0.56 ± 0.85 |
| Day 85 | -1.14 ± 0.72 | 0.64 ± 0.99 |
| Day 127 | -1.69 ± 1.14 | -0.31 ± 0.80 |
| Day 169 | -1.82 ± 0.78 | -0.62 ± 1.09 |
Polar section modulus is a measurement of bone strength and was derived from pQCT measurements. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Day 29 | 0.18 ± 0.78 | 0.02 ± 0.78 |
| Day 57 | -0.11 ± 1.08 | -0.46 ± 1.05 |
| Day 85 | -2.14 ± 1.40 | 0.93 ± 1.22 |
| Day 127 | -2.31 ± 1.55 | 1.76 ± 1.32 |
| Day 169 | -1.67 ± 1.14 | -1.05 ± 1.20 |
The polar strength strain index is a measurement of bone strength and was derived from pQCT measurements. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Day 29 | -1.85 ± 0.81 | -0.78 ± 0.51 |
| Day 57 | -1.32 ± 0.75 | -1.47 ± 1.21 |
| Day 85 | 0.36 ± 0.99 | -1.91 ± 1.49 |
| Day 127 | -0.71 ± 0.95 | -1.57 ± 0.94 |
| Day 169 | -0.41 ± 0.98 | -1.25 ± 0.78 |
Axial moment of inertia is an indicator of the ability of bone to resist bending, and was derived from pQCT measurements based on a circular ring model. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Day 29 | -0.22 ± 0.91 | -0.23 ± 0.73 |
| Day 57 | -0.19 ± 0.74 | -0.49 ± 0.88 |
| Day 85 | -1.90 ± 1.09 | 0.94 ± 0.83 |
| Day 127 | -0.90 ± 0.65 | 1.41 ± 1.04 |
| Day 169 | -1.25 ± 0.75 | -0.28 ± 0.98 |
Total bone area was assessed using peripheral quantitative computed tomography (pQCT), a 3-dimensional imaging technology which can be used for volumetric analysis of appendicular skeletal sites such as the arms and the legs. The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Day 29 | -2.30 ± 3.64 | -0.72 ± 2.35 |
| Day 57 | -5.11 ± 2.44 | -0.01 ± 3.66 |
| Day 85 | -0.27 ± 2.37 | 7.35 ± 3.21 |
| Day 127 | -0.43 ± 2.46 | 3.27 ± 2.96 |
| Day 169 | 1.90 ± 2.50 | 0.91 ± 3.32 |
Total bone mineral content was assessed using peripheral quantitative computed tomography (pQCT). The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Day 29 | 0.63 ± 0.43 | -0.30 ± 0.70 |
| Day 57 | 0.13 ± 0.53 | -0.09 ± 0.63 |
| Day 85 | 0.63 ± 0.56 | 1.16 ± 0.39 |
| Day 127 | 0.46 ± 0.56 | -0.14 ± 0.46 |
| Day 169 | 0.15 ± 0.59 | -0.64 ± 0.97 |
Total bone mineral density was assessed using peripheral quantitative computed tomography (pQCT). The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Day 29 | 4.45 ± 4.42 | 0.91 ± 1.97 |
| Day 57 | 6.22 ± 3.19 | 1.19 ± 2.98 |
| Day 85 | 1.52 ± 2.64 | -4.95 ± 2.33 |
| Day 127 | 1.43 ± 2.35 | -2.53 ± 2.38 |
| Day 169 | -1.14 ± 2.72 | -0.81 ± 2.59 |
Trabecular bone area was assessed using peripheral quantitative computed tomography (pQCT). The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Day 29 | -3.54 ± 5.68 | -0.64 ± 3.59 |
| Day 57 | -8.06 ± 3.86 | 0.43 ± 6.21 |
| Day 85 | -0.55 ± 3.82 | 12.00 ± 5.84 |
| Day 127 | -1.86 ± 4.01 | 5.60 ± 5.22 |
| Day 169 | 2.84 ± 4.18 | 1.57 ± 5.20 |
Trabecular bone mineral content was assessed using peripheral quantitative computed tomography (pQCT). The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Day 29 | -3.26 ± 7.35 | -0.52 ± 4.78 |
| Day 57 | -9.52 ± 4.68 | 0.02 ± 7.61 |
| Day 85 | 1.02 ± 5.51 | 14.64 ± 7.06 |
| Day 127 | -0.70 ± 6.15 | 5.68 ± 6.54 |
| Day 169 | 5.12 ± 5.55 | 1.74 ± 6.71 |
Trabecular bone mineral density was assessed using peripheral quantitative computed tomography (pQCT). The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Day 29 | -0.78 ± 1.88 | -0.34 ± 1.33 |
| Day 57 | -1.98 ± 1.16 | -1.30 ± 1.59 |
| Day 85 | 0.98 ± 1.64 | 2.00 ± 0.88 |
| Day 127 | 0.53 ± 1.92 | -0.49 ± 1.19 |
| Day 169 | 1.74 ± 1.47 | -0.51 ± 1.64 |
The polar strength strain index is a measurement of bone strength and was derived from pQCT measurements. The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Day 29 | 2.69 ± 2.36 | -0.14 ± 1.00 |
| Day 57 | 2.28 ± 1.47 | 1.28 ± 2.06 |
| Day 85 | 1.08 ± 1.71 | -0.90 ± 2.30 |
| Day 127 | -0.87 ± 1.29 | -0.89 ± 1.95 |
| Day 169 | -0.25 ± 1.61 | -1.51 ± 1.86 |
Bone mineral density was assessed using dual energy x-ray absorptiometry (DXA). Scans were analyzed by a central reader.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Day 29 | 1.715 ± 0.808 | 1.210 ± 0.814 |
| Day 57 | 0.832 ± 1.155 | -0.694 ± 0.827 |
| Day 85 | 0.790 ± 1.117 | -1.941 ± 0.986 |
| Day 127 | -0.118 ± 1.405 | -0.439 ± 1.346 |
| Day 169 | 1.866 ± 0.905 | -0.328 ± 0.702 |
Bone mineral density was assessed using dual energy x-ray absorptiometry (DXA). Scans were analyzed by a central reader.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Day 29 | 1.829 ± 0.617 | -0.555 ± 0.428 |
| Day 57 | 0.940 ± 1.081 | -1.651 ± 0.574 |
| Day 85 | 0.233 ± 0.996 | -1.690 ± 0.733 |
| Day 127 | 0.001 ± 1.081 | -0.369 ± 0.765 |
| Day 169 | 0.357 ± 1.237 | -0.649 ± 0.522 |
Bone mineral density was assessed using dual energy x-ray absorptiometry (DXA). Scans were analyzed by a central reader.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Day 85 | 0.345 ± 1.224 | 4.786 ± 0.846 |
| Day 169 | 0.149 ± 0.905 | 7.876 ± 1.351 |
| percent change | Placebo | Romosozumab |
|---|---|---|
| Day 4 | -4.40 ± 6.13 | 36.37 ± 10.02 |
| Day 15 | 3.46 ± 5.64 | 146.39 ± 20.00 |
| Day 29 | -0.33 ± 3.44 | 101.85 ± 19.97 |
| Day 57 | -6.93 ± 4.52 | 74.77 ± 10.91 |
| Day 62 | 0.27 ± 9.20 | 92.22 ± 14.71 |
| Day 71 | 19.61 ± 16.22 | 106.91 ± 14.08 |
| Day 85 | 23.83 ± 17.11 | 67.85 ± 19.11 |
| Day 99 | 10.94 ± 15.57 | 17.07 ± 11.79 |
| Day 127 | 5.49 ± 10.26 | 12.56 ± 8.57 |
| Day 169 | 20.85 ± 10.44 | 33.80 ± 13.64 |
| percent change | Placebo | Romosozumab |
|---|---|---|
| Day 4 | 6.62 ± 4.33 | -23.77 ± 7.78 |
| Day 15 | -2.29 ± 5.15 | -33.10 ± 8.85 |
| Day 29 | -3.19 ± 8.83 | -21.42 ± 13.98 |
| Day 57 | 7.87 ± 6.49 | 7.26 ± 16.28 |
| Day 62 | 8.69 ± 5.78 | -12.67 ± 15.15 |
| Day 71 | 5.60 ± 5.59 | -14.72 ± 13.84 |
| Day 85 | -3.00 ± 7.94 | 4.85 ± 19.28 |
| Day 99 | -9.14 ± 8.17 | 14.29 ± 23.73 |
| Day 127 | -10.00 ± 8.91 | 6.32 ± 16.60 |
| Day 169 | -3.61 ± 8.95 | 16.06 ± 20.53 |
Serum concentrations of romosozumab were measured by a validated enzyme-linked immunosorbent assay. The lower limit of quantification (LLOQ) was 50 ng/mL.
| days | Romosozumab |
|---|---|
| First dose | 3.0 (3.0 to 3.0) |
| Last dose | 5.0 (5.0 to 14) |
Serum concentrations of romosozumab were measured by a validated enzyme-linked immunosorbent assay. The lower limit of quantification (LLOQ) was 50 ng/mL.
| μg/mL | Romosozumab |
|---|---|
| First dose | 26.8 ± 6.4 |
| Last dose | 32.3 ± 9.6 |
Serum concentrations of romosozumab were measured by a validated enzyme-linked immunosorbent assay. The lower limit of quantification (LLOQ) was 50 ng/mL. The area under the serum drug concentration-time curve from time zero to tau (tau = 28 days) (AUC0-28) was calculated by the linear trapezoidal method.
| μg*day/mL | Romosozumab |
|---|---|
| First dose | 422 ± 75 |
| Last dose | 501 ± 179 |
Serum concentrations of romosozumab were measured by a validated enzyme-linked immunosorbent assay. The lower limit of quantification (LLOQ) was 50 ng/mL.
| μg*day/mL | Romosozumab |
|---|---|
| Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf) | 590 ± 240 |
Serum concentrations of romosozumab were measured by a validated enzyme-linked immunosorbent assay. The lower limit of quantification (LLOQ) was 50 ng/mL.
| mL/day/kg | Romosozumab |
|---|---|
| Apparent Clearance (CL/F) of Romosozumab | 5.82 ± 2.12 |
Serum concentrations of romosozumab were measured by a validated enzyme-linked immunosorbent assay. The lower limit of quantification (LLOQ) was 50 ng/mL.
| days | Romosozumab |
|---|---|
| Terminal Half-life (t1/2,z) of Romosozumab | 6.82 ± 0.92 |
Accumulation ratio was calculated as the ratio of AUC0-28 after the last dose to AUC0-28 after the first dose.
| ratio | Romosozumab |
|---|---|
| Accumulation Ratio | 1.15 ± 0.27 |
Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/12 (8.3%) | 10/12 (83.3%) |
| Romosozumab | — | 1/12 (8.3%) | 10/12 (83.3%) |
| Event | Placebo | Romosozumab |
|---|---|---|
| Gastrointestinal ulcer haemorrhageGastrointestinal disorders | 0/12 | 1/12 |
| Arthritis infectiveInfections and infestations | 0/12 | 1/12 |
| Cauda equina syndromeNervous system disorders | 1/12 | 0/12 |
| Event | Placebo | Romosozumab |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/12 | 1/12 |
| ConstipationGastrointestinal disorders | 2/12 | 1/12 |
| Injection site reactionGeneral disorders | 2/12 | 1/12 |
| Oedema peripheralGeneral disorders | 0/12 | 2/12 |
| Urinary tract infectionInfections and infestations | 2/12 | 0/12 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 2/12 | 1/12 |
| HypertensionVascular disorders | 2/12 | 2/12 |
| AnaemiaBlood and lymphatic system disorders | 1/12 | 0/12 |
| Abdominal distensionGastrointestinal disorders | 1/12 | 0/12 |
| DyspepsiaGastrointestinal disorders | 1/12 | 0/12 |
All treated participants
| Age, Continuous(years) | Placebo | Romosozumab | Total |
|---|---|---|---|
| Mean | 62.3 ± 5.6 | 65.6 ± 7.2 | 63.9 ± 6.5 |
| Age, Customized(Participants) | Placebo | Romosozumab | Total |
|---|---|---|---|
| 18 - 64 years | 9 | 6 | 15 |
| 65 - 74 years | 3 | 4 | 7 |
| ≥ 75 years | 0 | 2 | 2 |
| Sex: Female, Male(Participants) | Placebo | Romosozumab | Total |
|---|---|---|---|
| Female | 12 | 12 | 24 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Romosozumab | Total |
|---|---|---|---|
| White | 12 | 12 | 24 |
| Polar Moment of Inertia(mm⁴) | Placebo | Romosozumab | Total |
|---|---|---|---|
| Median | 1545.14 (932.79 to 2045.53) | 1496.50 (1162.51 to 2059.27) | 1501.96 (932.79 to 2059.27) |
No study locations are listed for this record.
Ran from Aug 2009 to primary completion in Aug 2010, 12 months.
Results were first posted in Jul 2019, 8 years 10 months after primary completion.
Of 13 phase 1 interventional studies under Bone Diseases, Metabolic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 37. This study's 12 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romosozumab